Published in Hepatology on May 01, 1998
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut (2003) 2.96
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol (2009) 1.44
Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci (2011) 1.44
Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol (2005) 1.35
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol (2008) 1.28
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Patients' preferences for treatment of hepatitis C. Med Decis Making (2009) 1.20
Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut (2004) 1.17
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci (2008) 1.04
Hepatitis C and liver transplantation. Gut (1999) 1.03
Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol (2008) 1.00
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol (2007) 0.96
A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci (2006) 0.95
Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol (2011) 0.92
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol (2016) 0.90
Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol (2008) 0.89
The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) (2005) 0.89
Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci (2011) 0.89
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol (2011) 0.89
Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy. Oncol Lett (2010) 0.89
Management of hepatocellular carcinoma in Japan. J Gastroenterol (2006) 0.87
Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol (2011) 0.87
Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol (2006) 0.86
Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol (2008) 0.86
The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit (2011) 0.86
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol (2011) 0.85
Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci (2002) 0.84
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PLoS One (2013) 0.82
Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol (2005) 0.81
Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut (2000) 0.81
Micrometastasis in surrounding liver and the minimal length of resection margin of primary liver cancer. World J Gastroenterol (2007) 0.80
A survey on herbal management of hepatocellular carcinoma. World J Hepatol (2011) 0.80
Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg (2008) 0.80
Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer (2012) 0.80
Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol (2012) 0.79
Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci (2011) 0.79
PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. Springerplus (2015) 0.79
Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. J Gastroenterol (2012) 0.78
Hepatocellular Carcinoma in a non-Cirrhotic Liver of a HCV-Positive Woman with Sustained Viral Response. Mediterr J Hematol Infect Dis (2011) 0.78
Occurrence of HCC in asymptomatic HCV-related chronic hepatitis. Dig Dis Sci (2002) 0.78
Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology (1998) 0.78
Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy. Surg Today (2007) 0.78
An analysis of risk factors for developing Hepatocellular carcinoma in a group of Hepatitis C patients with stage 3 fibrosis following interferon therapy. Cancer Inform (2008) 0.77
Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med (2012) 0.77
Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci (2003) 0.77
Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One (2015) 0.77
Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? J Clin Gastroenterol (2016) 0.77
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol (2006) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. J Gastroenterol (2016) 0.76
Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting. World J Surg Oncol (2014) 0.76
Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol (2006) 0.76
Prevention of hepatocellular carcinoma. HPB (Oxford) (2005) 0.76
Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2. World J Gastroenterol (2006) 0.76
Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon. Case Rep Gastroenterol (2009) 0.75
Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol (2015) 0.75
Antiviral therapy of HCV in the cirrhotic and transplant candidate. Int J Med Sci (2006) 0.75
Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer (2016) 0.75
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore) (2017) 0.75
Interferon therapy reduces the risk for hepatocellular carcinoma. Gut (2000) 0.75
Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut (2001) 0.75
Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut (2001) 0.75
Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Med Ultrason (2001) (2010) 0.75
Accumulation of 8-nitroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy. J Gastroenterol (2006) 0.75
The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Surg Today (2014) 0.75
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci (2017) 0.75
The close linkage between the elasticity modulus measured by real-time mapping shear wave elastography and the presence of hepatocellular carcinoma in patients with a sustained virological response to interferon for chronic hepatitis C. J Med Ultrason (2001) (2014) 0.75
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One (2017) 0.75
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun (1997) 14.09
High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med (2001) 12.49
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci (1995) 6.36
Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science (1997) 5.16
A giant nucleopore protein that binds Ran/TC4. Nature (1995) 4.36
Identification of the coding sequence for a reverse transcriptase-like enzyme in a transposable genetic element in Drosophila melanogaster. Nature (1985) 4.31
Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature (1994) 4.20
Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med (1994) 4.09
An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med (1999) 3.76
Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol (1996) 3.72
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (2000) 3.42
A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ (1996) 3.05
A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach. Infect Immun (1994) 2.94
Endoscopic resection of early gastric cancer. Endoscopy (1993) 2.88
Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol (1995) 2.84
Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol (1999) 2.77
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Neurotransmitter functions of mammalian tachykinins. Physiol Rev (1993) 2.59
Temperature-induced A-B intersite charge transfer in an A-site-ordered LaCu(3)Fe(4)O(12) perovskite. Nature (2009) 2.57
Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet (1997) 2.54
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol (1999) 2.44
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol (1999) 2.41
Infinite-layer iron oxide with a square-planar coordination. Nature (2007) 2.41
The relationship of preoperative magnetic resonance imaging findings and closed system drainage in the recurrence of chronic subdural hematoma. J Neurosurg (1997) 2.34
Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J (2001) 2.32
Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology (1992) 2.31
Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives. Chem Pharm Bull (Tokyo) (2000) 2.30
Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol (1994) 2.23
The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J (1996) 2.22
Genetic mutations in exons 3 and 4 of the pancreatic secretory trypsin inhibitor in patients with pancreatitis. J Gastroenterol (2001) 2.17
Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion (2001) 2.16
Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO J (1998) 2.13
Molecular cloning and functional characterization of a new Cap'n' collar family transcription factor Nrf3. J Biol Chem (1999) 2.09
Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. J Biol Chem (1997) 2.05
Structural characteristics of the PHO8 gene encoding repressible alkaline phosphatase in Saccharomyces cerevisiae. Gene (1987) 2.04
Establishment of a small animal model for human Helicobacter pylori infection using germ-free mouse. Am J Gastroenterol (1994) 2.00
Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology (1998) 1.97
Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene (2006) 1.94
JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway. Mol Cell Biol (1999) 1.90
Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology (2000) 1.87
Endoscopic therapy for early colon cancer: the strip biopsy resection technique. Gastrointest Endosc (1991) 1.86
Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest (1997) 1.82
Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med (1996) 1.81
Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology (1994) 1.80
Antifungal activity of ajoene derived from garlic. Appl Environ Microbiol (1987) 1.80
Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: implications for hepatitis C virus replication in infected tissue. Hepatology (1992) 1.77
The role of steroids and their effects on phospholipase A2. An animal model of radiculopathy. Spine (Phila Pa 1976) (1998) 1.77
Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol (2001) 1.77
A cDNA clone closely associated with non-A, non-B hepatitis. Nucleic Acids Res (1990) 1.76
Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res (1996) 1.74
Control of cell division by sex factor F in Escherichia coli. I. The 42.84-43.6 F segment couples cell division of the host bacteria with replication of plasmid DNA. J Mol Biol (1984) 1.73
Nonsurgical treatment of duodenal perforation by endoscopic repair using a clipping device. Gastrointest Endosc (1999) 1.72
Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol (1999) 1.72
Endoscopic ultrasonography and endoscopy for staging depth of invasion in early gastric cancer: a pilot study. Gastrointest Endosc (1997) 1.72
Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene (1999) 1.71
Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. Endocrinology (1999) 1.71
Morphologic studies of the liver cell dysplasia. Cancer (1983) 1.70
GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and definitive erythropoiesis. Proc Natl Acad Sci U S A (1997) 1.68
Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 1.67
Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest (1993) 1.66
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J (2000) 1.66
Balloon-occluded retrograde transvenous obliteration (BRTO), a promising nonsurgical therapy for ectopic varices: a case report of successful treatment of duodenal varices by BRTO. Am J Gastroenterol (1996) 1.65
Prospective randomized trial to compare the stapled double lumen pouch and the sutured quadruple pouch for restorative proctocolectomy. Br J Surg (1988) 1.64
Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. J Neurochem (2000) 1.64
Hepatitis C virus RNA in saliva. Lancet (1990) 1.62
IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol (1997) 1.62
Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology (1993) 1.61
Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol (2000) 1.61
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer (2007) 1.61
Gender and literacy: factors related to diagnostic delay and unsuccessful treatment of tuberculosis in the mountainous area of Yemen. Int J Tuberc Lung Dis (2005) 1.60
Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology (1993) 1.60
A new matrix protein family related to the nacreous layer formation of Pinctada fucata. FEBS Lett (1999) 1.60
The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol (1994) 1.59
Epstein-Barr virus-associated gastric carcinoma and atrophic gastritis. J Clin Gastroenterol (1999) 1.59
Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol (1997) 1.58
Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer (1998) 1.57
Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol (1997) 1.57
Alcoholic hyalin antigen (AHAg) and antibody (AHAb) in alcoholic hepatitis. Gastroenterology (1977) 1.57
Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology (Oxford) (2001) 1.56
Fluid shear stress stimulates big mitogen-activated protein kinase 1 (BMK1) activity in endothelial cells. Dependence on tyrosine kinases and intracellular calcium. J Biol Chem (1999) 1.55
Transmission of and liver injury by TT virus in patients on maintenance hemodialysis. J Gastroenterol (1999) 1.55
New small animal model for human gastric Helicobacter pylori infection: success in both nude and euthymic mice. Am J Gastroenterol (1991) 1.55
Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol (1984) 1.55
Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases. Gastroenterology (1979) 1.54
Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Pancreas (1999) 1.54
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther (1995) 1.53
Alternative promoters regulate transcription of the mouse GATA-2 gene. J Biol Chem (1998) 1.53
Effect of combined infusion of nitroglycerin and nicardipine on femoral-to-radial arterial pressure gradient after cardiopulmonary bypass. Anesth Analg (1990) 1.52
Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol (1999) 1.51
Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost (1996) 1.51
Mutation of an arginine biosynthesis gene causes reduced pathogenicity in Fusarium oxysporum f. sp. melonis. Mol Plant Microbe Interact (2001) 1.50
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology (1998) 1.50
Histone-like proteins are required for cell growth and constraint of supercoils in DNA. Gene (1992) 1.50